ArticleBritish journal of cancer2003
Prognostic significance of dysadherin expression in advanced colorectal carcinoma.
Article in British journal of cancer, 2003. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- Effect of E-cadherin on Prognosis of Colorectal Cancer: A Meta-Analysis Update.Molecular diagnosis & therapy · 2022Pooled it
- Prognostic value of dysadherin in cancer: A systematic review and meta-analysis.Frontiers in oncology · 2022Pooled it
- Downregulated E-cadherin expression indicates worse prognosis in Asian patients with colorectal cancer: evidence from meta-analysis.PloS one · 2013Pooled it
- The dysadherin/carbonic anhydrase 9 axis shapes an acidic tumor microenvironment to promote colorectal cancer progression.Signal transduction and targeted therapy · 2026Article
- The dysadherin/MMP9 axis modifies the extracellular matrix to accelerate colorectal cancer progression.Nature communications · 2024Article
- The dysadherin/FAK axis promotes individual cell migration in colon cancer.International journal of biological sciences · 2024Article
- Article
- MMP8 increases tongue carcinoma cell-cell adhesion and diminishes migration via cleavage of anti-adhesive FXYD5.Oncogenesis · 2021Article
- Low expression of FXYD5 reverses the cisplatin resistance of epithelial ovarian cancer cells.Histology and histopathology · 2021Article
- Cadherins down-regulation: towards a better understanding of their relevance in colorectal cancer.Histology and histopathology · 2020Review
- Prognostic and Clinicopathological Significance of EphB3 and Dysadherin Expression in Extrahepatic Cholangiocarcinoma.Cancer management and research · 2020Article
- Dysadherin specific drug conjugates for the treatment of thyroid cancers with aggressive phenotypes.Oncotarget · 2017Article
- Clinicopathologic Correlations of E-cadherin and Prrx-1 Expression Loss in Hepatocellular Carcinoma.Journal of pathology and translational medicine · 2016Article
- Alterations in dysadherin expression and F-actin reorganization: a possible mechanism of hypericin-mediated photodynamic therapy in colon adenocarcinoma cells.Cytotechnology · 2015Article
- Prognostic implications of adhesion molecule expression in colorectal cancer.International journal of clinical and experimental pathology · 2015Article
- Differential expression of dysadherin in papillary thyroid carcinoma and microcarcinoma: correlation with E-cadherin.Endocrine pathology · 2008Article
- In breast carcinoma dysadherin expression is correlated with invasiveness but not with E-cadherin.British journal of cancer · 2007Article
- E-cadherin expression pattern in primary colorectal carcinomas and their metastases reflects disease outcome.World journal of gastroenterology · 2006Article
- Chemokine (C-C motif) ligand 2 mediates the prometastatic effect of dysadherin in human breast cancer cells.Cancer research · 2006Article
- Slug expression is an independent prognostic parameter for poor survival in colorectal carcinoma patients.British journal of cancer · 2006Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A novel glycoprotein, dysadherin, has an anti-cell - cell adhesion function through downregulating E-cadherin. In this study, we investigated the expressions of dysadherin and E-cadherin in 82 patients with stage II and III colorectal carcinomas to determine the correlation between the two molecules and the clinicopathologic features of each tumour. Dysadherin was not expressed in normal colorectal epithelium. Fifty-one per cent of tumours showed dysadherin immunopositivity in over 50% of cancer cells. Thirty-eight per cent of tumours showed reduced E-cadherin immunopositivity. The increased expression of dysadherin was significantly associated with lung metastasis (P=0.003). The increased expression of dysadherin had a significant impact on patient survival (P=0.0099 and 0.0036, log-rank test for overall and recurrence-free survival rate, respectively). Furthermore, tumour with increased expression of dysadherin and reduced expression of E-cadherin showed the worst prognosis (P=0.0043 and 0.0028, log-rank test for overall and recurrence-free survival rate, respectively). These results suggest that increased dysadherin expression is a significant indicator of poor prognosis for patients with advanced colorectal carcinoma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.